Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer's disease.

For the 20 mg/kg group, while there was a trend in reduction in both hippocampal and frontal cortex TREM2 levels, it did not reach statistical significance.

also in 111,027 other papers

In the 80 mg/kg group, hippocampal TREM2 levels were significantly reduced compared with controls ( p < 0.001), while the reduction in TREM2 levels in frontal cortex did not achieve significance by one-way ANOVA.

also in 1,397 other papers